Good MorningEquity markets rebounded from Wednesday's Fed-induced sell-off, but Thursday's action gives little reason to think the selling is over. The S&P gained less than 1% to trade in the lower half of the previous day's range, creating a Harami candle pattern signaling the sell-off has the potential to gain strength. A move to retest Wednesday's low is likely, and a move to new lows is possible. The market could fall as low as 5,700 in that scenario before the S&P 500 hits firm support.
Today will be a test for the market. The PCE Price Index is due and expected to confirm inflation is rising. A hot report will strengthen the Fed's resolve, possibly leading them to reduce the rate cut outlook again and give the market a reason to sell. The silver lining is that the underlying causes of high inflation are demand and economic health, which are drivers of corporate earnings and bullish for stocks. Featured: AI Meltdown Imminent: Dump These Stocks Now! (Ad) 
|
Stocks | | | U.S. stocks rose Friday to turn what would have been one of the market’s worst weeks of the year into just a pretty bad one.The S&P 500 rallied 1.1% for its best day in six weeks and shaved its loss for the week down to 2%. The Dow Jones Industrial Average jumped 498 points, or 1.2%, and the Nas... Read the Full Story |
|
From Our PartnersBehind closed doors, away from the mainstream media's eyes, the smartest minds in crypto are all seeing the same signals. They're positioning themselves for something unprecedented.
And after 17 million podcast downloads and over 600 insider interviews, I finally connected all the dots…
What I discovered was so explosive, so potentially life-changing, that I had to put it all in a book. | | | Claim your FREE copy of Crypto Revolution now. |
|
Markets | | |
The most upgraded stocks at year’s end in 2024 are NVIDIA (NASDAQ: NVDA), Amazon (NASDAQ: AMZN), and Meta Platforms (NASDAQ: META). Each received more than 120 positive revisions, including price target increases and upgrades that have lifted their markets significantly. The question is... Read the Full Story |
|
Markets | | |
As years go by, 2024 has not been a great one for shares of SolarEdge Technologies Inc (NASDAQ: SEDG). The $800 million market cap stock is down 85% since the start of January, which means it’s back trading at 2016 levels. For any investor that was involved in SolarEdge in the 8 years s... Read the Full Story |
|
From Our Partners2025 is off to a turbulent start—markets are swinging wildly, inflation pressures remain high, and recession fears are creeping back into headlines.
But even in uncertain times, innovation doesn’t slow down.
In fact, artificial intelligence (AI) is accelerating faster than ever—creating new profit opportunities while the broader market struggles.
Our latest research reveals two AI stocks trading under $15 that could thrive even as volatility grows. These under-the-radar companies are positioned to ride the next wave of AI-driven demand—and they’re still flying below most investors’ radar. | | | 👉[Click here to access your FREE AI stocks report now.] |
|
Markets | | | At a time when many stocks are objectively and historically overvalued, many investors are wondering where they should put their investable capital in 2025. Some stocks that should attract your attention are trading for less than $10. These stocks allow investors to accumulate a significant number o... Read the Full Story |
|
Markets | | | In the midst of companies looking to implement AI and investors looking for a way to profit from the trend, up-and-coming AI firms continue to pop up. Below, I’ll detail three small-cap AI stocks to watch out for in 2025. Two have had great 2024s and are looking to continue their strong showin... Read the Full Story |
|
From Our PartnersJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%...
Just did a demo of what Nvidia’s CEO said will be "the first multitrillion-dollar robotics industry." | | | Click here to watch the demo… |
|
Markets | | | Investors interested in Micron Technology (NASDAQ: MU) should cheer the fact that its stock tanked following the FQ1 2025 earnings report. The move is a knee-jerk reaction to mixed results and guidance that point to near-term weakness and long-term strength, driven by its shift to AI.
The l... Read the Full Story |
|
Markets | | | Russia's central bank has left its benchmark interest rate at a record 21%, holding off on further increases despite high consumer inflation fueled by the Kremlin's war against Ukraine. The decision Friday comes amid criticism from influential business figures, including tycoons close to the Kremlin... Read the Full Story |
|
Markets | | | The U.K.’s central bank has warned about “heightened uncertainty” as it kept interest rates on hold after inflation moved further above target even at a time when the British economy is flatlining at best Read the Full Story |
|
Markets | | | Lamb Weston, a major supplier of frozen French fries to global chains like McDonald’s, KFC and Taco Bell, has named a new CEO after posting a surprise loss in the second quarter as consumers pull back on the money they spend on food outside the home Read the Full Story |
|
Markets | | | The American economy grew at a healthy 3.1% annual clip from July through September, propelled by vigorous consumer spending and an uptick in exports, the government said in an upgrade to its previous estimate Read the Full Story |
|
Friday's Early Bird Stock Of The Day Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom. | | View Today's Stock Pick |
|
